Engaged in the research and development production and promotion of new veterinary vaccines
"Eliminate hidden dangers of accidents and build a strong line of defense"-Huizhong Biotech "Safe Production Month" event2020-07-02
In order to further popularize safety knowledge, effectively improve employees' safety awareness, responsibility awareness, and legal awareness, and enhance the company's safety management level, on June 24, Huizhong Biological held the second "Ankang Cup" safety knowledge competition.More
The Henan-scale pig farm diarrhea prevention and control high-end summit ended successfully2020-08-31
From August 25th to 26th, Luoyang Huizhong Biotechnology Co., Ltd. held the "Henan Scale Pig Farm Diarrhea Prevention and Control Summit" at its Luoyang headquarters. More than 20 guests from Henan large-scale pig farms participated in the meeting. The company specially invited Professor Wang Chuanqing, a doctoral supervisor of Henan Agricultural University, a member of the Expert Committee of Animal Disease Prevention and Control of the Ministry of Agriculture, and an assistant to the director of the National Veterinary Medicine Engineering Technology Research Center. Dr. Xiuling participated in this summit. The purpose of this summit is to provide a platform for learning and communication for large-scale pig farms in Henan, and to promote the sharing of new swine disease clinical experience and results.More
Don't forget the original intention and move forward | Huizhong Biological holds the 2020 autumn running competition2020-11-30
This month, Luoyang Huizhong Biotechnology Co., Ltd. held the 2020 Fall Running Competition in Luopu Park. A total of 79 employees from the company's sales system participated in the competition.More
Qunying "decodes" the future trend of veterinary chemicals2015-09-23
On the afternoon of September 16, the veterinary drug industry development and animal product safety high-level forum on chemical drugs and Chinese veterinary drugs was held in the VIP room on the third floor of the Lihao International Hotel in Luoyang. Li Xiangdong, vice president of the China Veterinary Medicine Association, gave a speech to thank the Veterinary Administration, the Central Supervision Institute, and the Henan Provincial Bureau for their strong support, and the positive responses of the leaders of the backbone enterprises in the veterinary drug industry and all the business representatives present. He pointed out that the center of the conference is "innovation", "technology innovation, management innovation, economic marketing innovation", and innovative concepts and thinking are the original intention to promote the development of the industry.More
Xu Shixin, Director of the Safety Evaluation Office of China Veterinary Drug Supervision Institute-Decrypting the "Resistance Prohibition Order"
Director Xu Shixin first introduced the international standards for the use of antibiotics and enumerated the problems of food safety and environmental pollution caused by several drugs cancelled by the United States and the European Union. It is estimated that 8.424 (16.2×52%) ten thousand tons of antibacterial drugs used in my country’s aquaculture industry in 2013 are used together. my country needs to use 987 g antibacterial drugs per ton of meat produced. The EU standard Denmark uses 40-50 g antibacterial drugs per ton of meat. The difference is nearly 20 times, indicating that there is an excessive use of antibacterial drugs in my country. The Ministry of Agriculture cancelled the four antibacterial drugs of the class of floxacin because they are shared by humans and animals and there is no food safety standard, MRL.
He especially emphasized not to misinterpret "anti-antibiotics". It should be understood as "anti-antibiotics" to restrict the use of antibacterial drugs. Antibacterial drugs are not used for food animals and pets can use them. The key is to use them cautiously and rationally.
Director Xu Shixin advocates strengthening the research and development of herbivore anti-parasitic drugs, research and development of animal-specific antibacterial drugs, research and development of animal-specific drugs, do not share the definition of new veterinary drugs, drugs that are not available at home and abroad, and extend the protection period of new veterinary drugs: 1. 10 years for Class II drugs, 7 years for Class II drugs, 5 years for preparations, increase innovative scientific research support, and promote GLP/GCP service outsourcing, especially safety evaluation service outsourcing.
Professor Zeng Jianguo from Hunan Agricultural University-"Innovation of Chinese Veterinary Medicine and Development of Feeding Plants"
The market for veterinary Chinese herbal medicines and Chinese herbal medicine plants in the breeding industry overlap, and attention should be paid to the development of veterinary Chinese medicines and feed plants. Chinese veterinary medicines and human medicines are not intersected, and feed resources are parts that are not used in human medicine or are rarely used. Location. The research and development of Chinese herbal medicine for veterinary use is a necessary means to control the cost of feed additives.
Li Chaoyang, Chairman of Shandong Xinde Technology Co., Ltd.-"How to Transform Traditional Veterinary Drug Enterprises under the New Normal"
The "new normal" for veterinary drug companies is the further adjustment of the structure of breeding enterprises, the large-scale and intensified breeding. Food safety has become a survival factor for aquaculture companies, and the trough of the aquaculture industry has prolonged. Large veterinary drug companies that have been blessed by the capital market have become more willful, and the two-dimensional code is mandatory. The transformation of veterinary drug companies includes biological products, raw materials, and traditional Chinese medicine extraction with relatively higher entry barriers, product upgrades, improved efficacy of generic drugs, search for new pet and fur markets, shrinking competition areas, and transformation to the Internet (Internet + or + Internet). In addition to the determination and will of the leader, the factors for successful transformation must have a resource base and the establishment of organizational capabilities to adapt to the new business model.
Li Shoujun, President of Tianjin Ruipu Biotechnology Co., Ltd.-"Thinking about the transformation and development trend of the veterinary drug industry"
Mr. Li first introduced the current situation and challenges faced by my country's veterinary drug companies: ①The veterinary drug companies are small and scattered, with low industrial concentration and overcapacity; ②The evaluation methods and efficiency of veterinar
International bird flu epidemic is spreading! Japan will culled more than 90,000 feathers from the 25th!2020-11-30
Japan and China just agreed to start business trips affected by the epidemic this month. However, it was reported that chickens from a chicken farm in Mongxiang City, Fukuoka Prefecture, Japan have died and the H5 avian influenza virus has been detected. The Fukuoka Prefectural Government held a meeting of the Countermeasures Headquarters at 5 am today (November 25) and decided to start the culling of 93,500 chickens raised in the chicken farm from now on, and required this task to be completed within 3 days.More
In addition to the decision of the Fukuoka Prefecture government to culminate more than 90,000 chickens, it also requires that chickens and eggs within a radius of 3 kilometers of the chicken farm be prohibited from moving to other places, and chickens and eggs within a radius of 10 kilometers are prohibited from being shipped. NHK previously reported that Japan’s Ministry of Agriculture, Forestry and Fisheries has confirmed that the first case of H5 avian influenza virus tested in a chicken farm in Kagawa Prefecture is a high-fatality H5N8 highly pathogenic avian influenza. Japanese experts have determined that it may have entered Japan via Siberia. At this stage, the possibility of infection to humans is very low.
Chinese Center for Disease Control and Prevention Prompts to Prevent Human Infection with Avian Influenza2020-12-31
On December 26, the Chinese Center for Disease Control and Prevention reminded people to prevent human infection with avian influenza. Since the beginning of winter, my country has discovered avian influenza epidemics among poultry. Several sporadic cases of human infection with avian influenza have also been reported in a few areas in southern my country. The main source of human infection with avian influenza is contact with infected live poultry or visits to contaminated live poultry markets. In the initial stage, patients generally present with flu-like symptoms, such as fever, cough, and low sputum, which may be accompanied by headache, muscle aches, and general malaise. The condition of severely ill patients develops rapidly, and most of them show severe pneumonia and other manifestations.More
New progress has been made in the breeding of new breeds of livestock and poultry at the Chinese Academy of Agricultural Sciences2021-01-29
In recent years, the Chinese Academy of Agricultural Sciences has cultivated a number of new breeds of livestock and poultry to help ensure the safety of the national seed industry in response to the country’s major needs for the livestock and poultry seed industry.More
This is what the reporter learned from the press conference of "Science and Technology Innovation Leading the High-Quality Development of Livestock and Poultry Seed Industry" held by the Chinese Academy of Agricultural Sciences a few days ago.
Qin Yuchang, director of the Beijing Institute of Animal Husbandry and Veterinary Medicine of the Chinese Academy of Agricultural Sciences, said that meat, eggs and milk are an important variety of people's "vegetable baskets". At present, the independent innovation level and provenance guarantee ability of my country's livestock and poultry seed industry continue to improve, and the main livestock and poultry core species source rate exceeds 75%.
During the "13th Five-Year Plan" period, the Chinese Academy of Agricultural Sciences strengthened the cultivation of new domestic livestock and poultry varieties and made new progress:
With Beijing oil chicken as the material, the "Liyuan oil chicken egg chicken" and "Jingxing yellow chicken 103" broiler chicken line were cultivated. On the basis of maintaining the meat and egg quality and flavor, the egg production, fecundity and feed conversion efficiency were significantly improved .
Using Beijing duck as the material, two lean meat duck supporting lines have been cultivated. In 2020, the number of promotion will reach 1.2 billion, accounting for 36.5% of the national market, breaking the monopoly of foreign varieties. A special supporting line for roast duck has been cultivated, and the traditional duck filling method is no longer used.
In beef cattle breeding, the new beef breed "Huaxi Cattle" (tentative name), which is a crossbreeding of Simmental cattle and Chinese local cattle, is planned to pass the national new breed certification before 2022, which is expected to break the main dependence on imported beef cattle germplasm situation. In 2020, the first Chinese beef and fine beef tasting event was organized, and a number of local breeds were introduced. The "Pingliang Red Bull" that is being cultivated is expected to become a special beef breed.
At the same time, the Chinese Academy of Agricultural Sciences has cultivated the "Alpine Merino Sheep", achieving a major breakthrough in the cultivation of alpine fine-wool sheep, and co-cultivating a new breed of "Luxi Blackhead Sheep" with the local area to adapt to house-raising in northern farming areas. Utilizing domestic and foreign pig genetic resources, we have carried out the breeding of "Zhonghu No. 1" and "Zhonghu No. 2" fine pig breeds, and completed multi-generation breeding, which will provide support for the transformation and upgrading of the pig industry.
The Central Economic Work Conference proposed that it is necessary to carry out technical research on seed source "stuck neck", and is determined to fight a turnaround in the seed industry.
It is reported that during the "14th Five-Year Plan" period, the Chinese Academy of Agricultural Sciences will make arrangements for livestock and poultry germplasm resources, major species cultivation, condition and capacity building, and industrialization of results, promote the construction of the national livestock and poultry germplasm resources bank, and strengthen livestock and poultry germplasm resources. Biological breeding basic research and technological innovation research, strengthen the integration of science and technology enterprises to promote the industrialization of livestock and poultry breeding.
Talking about the industry, the wings of dreams enlighten the future2015-09-23
Facing the new situation of Internet, capital, breeding and the development status of veterinary biological products industry, on the afternoon of the 16th, the biological products sub-forum of the veterinary drug industry development and animal product safety high-level forum set up face-to-face interactive activities. Chaired by Hu Qiyi, Chairman of China Animal Husbandry Industry Co., Ltd., Gu Hong, Director of the Pharmaceutical Administration Department of the Veterinary Administration of the Ministry of Agriculture, Li Wanmeng, Executive General Manager of Merial China, Sun Jinzhong, General Manager of Placo Bioengineering Co., Ltd., Beijing Zhongliankang Biotechnology Co., Ltd. Chairman Kuang Huixing, Chairman Sun Hao of Beijing Huaduyu Poultry Industry Co., Ltd., General Manager Wang Yongsheng, Jinyu Baoling Biopharmaceutical Co., Ltd., General Manager Fan Gencheng, Qingdao Yibang Biological Engineering Co., Ltd., and Wu Dongxun, China Animal Husbandry Industry Co., Ltd. The general manager participated in the communication session. In this session, representatives of various companies raised sharp questions, and they were all answered wonderfully by industry leaders and experts.More
Question: In the development of the biological products industry, as a regulator, can you examine from the perspective of the company, what needs to be improved or create more conditions for the company?
Hong Gu, Director of the Pharmaceutical Administration Department of the Veterinary Administration of the Ministry of Agriculture: "Before this year, the "Industry Guidance Opinions" will be issued, which will add content related to the reform of the new industry system. The next step will be revised one by one, and the system will be implemented. The reform system includes enterprises Concerned about the reform of the "Veterinary Drug Evaluation System", update the settings and refine the evaluation mechanism of veterinary drugs (registration categories of different veterinary drugs, different evaluation indicators), and reform the concept of new veterinary drugs, not "arbitrarily" eliminated, but changed Use scientific methods to evaluate the situation and contribute to the promotion of enterprise development.
2. The gap
Question: What is the gap between Chinese veterinary drugs and foreign countries?
Wang Yongsheng: In fact, there is no significant difference between our country’s veterinary drugs and foreign countries, and what my country needs to strengthen is: ① Innovation: Compared with our country, foreign platforms are broader, which can graft different products (vaccine) and are suitable for enterprises. Therefore, when my country is developing new products, it is better to build several such communication platforms, which can broaden perspectives and generate more new ideas; ②Promote sales: companies not only produce, but also use data to consolidate Existing position in the market; ③Improvement: Any benefit about products comes from the fundamental quality, and it is necessary to improve the GMP inspection system.
3. Network "win-win"
Q: How to create value for customers?
Sun Jinzhong: Take the layer customers as an example. The Internet in the layer field aims to create value for customers. It sets up multiple service points in the front line, which not only sells the customers needed (biological products, feed products, etc.), but also sells the customers' eggs. The purchase of chicken and egg rice forms a "dual-phase economy".
4. The Chinese market
Q: How does Merial view the Chinese market?
Li Wanmeng: ①China’s traditional consumption of pork will not change; ②Food consumption and poultry meat consumption will definitely increase; ③With the continuous improvement of people’s living standards and the aging population, the pet market will definitely increase; ④Rumination of cattle, sheep, etc. For animals, due to the "zero tariff" imports of New Zealand and Australia, it will have a great impact on the Chinese market.
5. The logical starting point should be considered from the perspective of the enterprise
Qin Dechao, General Manager of Qian Yuanhao: Regardless of the current system or the direction of future reforms, what is the logical starting point and legal basis for the approval of veterinary drugs, especially biological products?
Gu Hong, Director of the Department of Pharmaceutical Affairs, Ministry of Agriculture: We can only make a relatively achievable adjustment under the current legal framework of the "Regulations on Administration of Veterinary Drugs." It's not a matter of a few words, overnight. In the past two years, we have been working on the revision of the "Veterinary Drug Product Approval Number", which is expected to be released by the end of the year. The new "Veterinary Drug Product Approval Number" will have many regulations equivalent to the prevention and treatment system of human drugs, which will increase the protection of new vete
Where is the industry going after the big changes? Lian Miao leads the scientific burden of disease prevention and control-Huizhong Biotech's launch conference2017-07-09
(New animal husbandry news from Luoyang) At present, my country's poultry breeding industry is rapidly moving towards "scale, standardization, intelligence and ecologicalization", but the epidemics continue, the preventive and health care medication is disordered, and the vaccine immunity is complicated. It is still a problem that plagues the rapid development of the poultry breeding industry. How to "scientifically reduce the burden and healthy breeding" is a topic that the industry needs urgent attention to.More
On July 6, 2017, Luoyang Huizhong Biological Technology Co., Ltd. (hereinafter referred to as Huizhong Biological) held in Luoyang, Henan, a forum on new models of cost-saving and efficiency-enhancing immunization and the listing of new methods with the theme of "Scientific Burden Reduction, Win-Win Cooperation" At the press conference, about 200 industry professionals, experts, scholars, and media personnel from all over the country were invited to interpret the new model of poultry disease prevention and control, and explore new trends in the research and development of biological products for poultry.
Hu Wei, General Manager of Luoyang Huizhong Biotechnology Co., Ltd.
Hu Wei, general manager of Huizhong Biological, said in a speech that the emergence of the new series of joint seedlings has made a significant contribution to the field of poultry seedlings in my country, and has made outstanding contributions to the prevention and control of industry diseases. In the future, Huizhong Biology will develop a series of genetically engineered vaccines combining Newcastle disease (gene VII), bursa of fabric (rVP2 protein), and adenovirus genetic engineering subunits, as well as water-based adjuvant vaccines for broilers. The pig vaccine was officially launched in October this year.
The general trend of genetic engineering vaccines
Zhang Xuke, Chairman of Plyco Bioengineering Co., Ltd.
my country’s animal husbandry industry is in a period of rapid development of intensive and branding, and the scale of the pig and poultry industry has increased significantly. Zhang Xuke, chairman of Plyco Bioengineering Co., Ltd. (hereinafter referred to as Plyco), believes that environmental protection pressure and food safety , Rising labor costs and economies of scale are the driving forces leading to these changes. Large-scale breeding groups and breeding cooperatives/family farms will become the main breeding methods in the future.
For the animal protection industry, the industry concentration has also continued to increase. In 2015, there were 88 biological products companies, of which the output value of the top 10 accounted for 71%, and the output value of the top 5 accounted for 48%; there were 1,720 chemical pharmaceutical companies in 2015. The output value of the top 30 accounts for 51%. In addition, industry restructuring and mergers and acquisitions have intensified, with strong companies acquiring relatively weak companies, or strong alliances, and competition for resource integration is fierce. Third, the integration of the industrial chain of enterprises has accelerated, and large enterprises have expanded from feed and animal husbandry to numerous examples. Fourth, technological innovation has become the consensus of industry development, and the number of new veterinary drug registration certificates has increased year by year.
In recent years, the joint-stock company has increased its scientific and technological innovation and achieved remarkable results. It has successively obtained 31 national new veterinary drug certificates, established 53 veterinary drug national standards, obtained more than 120 authorized invention patents, more than 390 invention patent applications, and obtained 10 national and provincial patents. Municipal Science and Technology Progress Award, becoming one of the giants in the animal protection industry.
Regarding Huizhong's future development strategy, Zhang Xuke introduced that a new generation of genetically engineered vaccines is an important direction for the company's development. In addition, efficient immune adjuvant technology, a new generation of high-throughput rapid diagnostic kits, and animal health management And the ecological circle of safe animal product production.
Tian Kegong, Director of National Engineering Research Center for Veterinary Medicines
Poultry vaccines have developed to the third generation of vaccines, namely genetic engineering technology + bioengineering technology. Tian Kegong, director of the National Veterinary Medicine Engineering Technology Research Center, introduced that genetic engineering vaccines are vaccines prepared by genetic engineering methods, that is, using genetic recombination technology. The vaccine prepared by inserting natural or artificial genetic material into other vectors such as bacteria to fully express it and then purify it. Compared with traditional vaccines, genetic enginee
China‘s first aqueous adjuvant, porcine circovirus type 2 and mycoplasma hyopneumoniae dual inactivated vaccine is grandly launched2018-11-08
On November 6, 2018, the launch conference of the water adjuvant porcine circovirus type 2 and Mycoplasma hyopneumoniae dual inactivated vaccine developed over 8 years was grandly held in Luoyang. This water adjuvant porcine circovirus type 2 and Mycoplasma hyopneumoniae dual inactivated vaccine was developed by Luoyang Huizhong Biotechnology Co., Ltd. relying on the National Veterinary Medicine Engineering Technology Research Center.More
Luoyang Huizhong Biotechnology Co., Ltd. is a wholly-owned subsidiary of Plyco Bioengineering Co., Ltd., a leader in domestic animal protection technology innovation. It was established in 2011 and has been successfully operated in Luoyang Huizhong Veterinary Medicine for 20 years. Plyco Bio has successfully operated Born on the basis of 10 years, it passed the GMP acceptance of the Ministry of Agriculture in May 2015. Mainly engaged in the research and development, production and operation of veterinary biological products and drugs, it is a high-tech enterprise, and its innovation ability and comprehensive strength are among the best in the industry. Huizhong Biotechnology has always adhered to the development concept of "innovation to achieve the future, decent and stable operation", relying on the scientific research platform of the National Veterinary Medicine Engineering Technology Research Center to realize the transformation of scientific and technological achievements.
Huizhong Biotechnology has successively obtained 8 national new veterinary drug certificates and more than 6 national invention patent authorizations. Successively developed the new-flow method triple inactivated vaccine known as the "one-day-old immunization expert", the domestic water adjuvant porcine circovirus type 2 and mycoplasma pneumonia double inactivated vaccine, which has contributed to the technological advancement of my country's veterinary drug industry and animal Disease prevention and control and animal product safety provide excellent technical and product support.
The "Porcine Circovirus Type 2 and Mycoplasma Hyopneumoniae Dual Inactivated Vaccine" that is listed this time is Huizhong Biotechnology Co., Ltd. adhering to the business philosophy of "decent and stable operation" and pursuing the development strategy of "innovation for the future". Relying on the major scientific and technological achievements made by the National Veterinary Drug Engineering Technology Research Center as a technology platform, it has independent intellectual property rights and has obtained the national new veterinary drug registration certificate. This result is another masterpiece obtained through continuous innovative practice since Huizhong's biological adjuvant porcine circovirus type 2 inactivated vaccine (SH strain II)!
Huizhong Biological Water Adjuvant Porcine Circovirus Type 2 Inactivated Vaccine (SH strain II), leading the domestic water adjuvant whole virus inactivated vaccine, has played a major role in the prevention and control of my country's porcine circovirus disease since the product was successfully launched , Creating good economic and social benefits; relying on the National Veterinary Medicine Engineering Technology Research Center, the company continues to conduct research and development and technological innovation and upgrades for the prevention and control of the epidemic, and develops newer and safer vaccines.
The project team used special water adjuvants and advanced seedling production technology to effectively avoid the risks of adjuvant, antigen incompatibility, stability and uniformity after single seedlings were mixed, and successfully isolated, evaluated and screened Mycoplasma strains with good immunogenicity and growth. Developed a safe and efficient water-based adjuvant suitable for two antigens, solved the three major technical problems of compatibility between PCV2 and mycoplasma antigens, and successfully developed the domestic water adjuvant porcine circovirus type 2 and mycoplasma hyopneumoniae Inactivated vaccine. The successful development and listing of this product is of great practical significance for promoting technological progress and product upgrades in the industry, and improving the level of disease prevention and control.
Background of the project:
Porcine circovirus type 2 (PCV2) can cause multiple system failure syndrome (PMWS) in weaned piglets, porcine dermatitis and nephrotic syndrome (PDNS), porcine respiratory complex disease (PRDC), sow reproductive disorder (PRF), piglet A series of diseases such as congenital tremor (CT), which are easily mixed with other pathogens or lead to secondary infections, increase the clinical complexity, thereby causing huge economic losses to pig farms and serious impacts on the global pig industry .
Mycoplasma hyopneumoniae is a chronic respiratory disease caused by infection with Mycoplasma hyopneumoniae. It is also known as "swine asthma" or "swine endemic pneumonia". After Mycoplasma hyopne
The porcine circovirus type 2 vaccine is first released on the market, with one injection and two preventions, and pig raising is more worry-free!2018-11-08
On November 6, 2018, Luoyang Huizhong Biotechnology Co., Ltd. (a wholly-owned subsidiary of Plyco Bioengineering Co., Ltd.) relied on the water adjuvant porcine circovirus 2 developed by the National Engineering Research Center for Veterinary Medicine for 8 years The press conference for the launch of the combined inactivated vaccine against mycoplasma hyopneumoniae and mycoplasma was held in Luoyang.More
"Porcine circovirus type 2 and Mycoplasma hyopneumoniae dual inactivated vaccine" is Huizhong Biotechnology Co., Ltd. adhering to the business philosophy of "decent and stable operation", pursuing the development strategy of "innovating for the future" and relying on the national veterinary drug project. The Technology Research Center has achieved major scientific and technological achievements for the technology platform, has independent intellectual property rights, and has obtained the national new veterinary drug registration certificate. This result is another masterpiece obtained through continuous innovative practice since Huizhong's biological adjuvant porcine circovirus type 2 inactivated vaccine (SH strain II)!
In recent years, with the continuous deepening of my country’s agricultural and animal husbandry industrialization reforms, it has facilitated the sustainable development of my country’s animal husbandry. The species and number of livestock and poultry have increased significantly, and the types and frequency of livestock and poultry diseases have also increased. greatly increase. In clinical morbidity, mixed infection is a common phenomenon, especially the mixed infection of circovirus type 2 and Mycoplasma hyopneumoniae is more common. Therefore, the combined vaccine that can prevent multiple diseases is the current development trend of veterinary biological products, and it is also a breeding enterprise. Urgently needed products. Although there are mature commercial vaccines for the prevention and control of these two pathogens, there are many types and complicated immune procedures. Therefore, the combined vaccine of circovirus type 2 and Mycoplasma hyopneumoniae can make up for the single vaccine in the application process. A series of shortcomings achieve the effect of one needle and two defenses, saving time and effort.
The "Porcine Circovirus Type 2 and Mycoplasma Hyopneumoniae Dual Inactivated Vaccine" launched by Huizhong Biotechnology has completely independent intellectual property rights. It is the first to complete product development and obtain a new veterinary drug certificate; special water adjuvants cooperate with advanced manufacturing The seedling technology guarantees the quality of the combined seedlings, and one injection and two preventions can effectively avoid the risks of adjuvant, antigen incompatibility, poor stability and uniformity after single seedlings are mixed.
1. Domestic isolated bacterial strains are more suitable for Chinese pig farms: Mycoplasma hyopneumoniae is selected domestically isolated popular strain HN0613. The nucleotide sequence analysis of the P97 gene R1 region shows that its homology rate with domestic isolated strains is much higher than that of foreign strains. Laboratory immune challenge and clinical use have proved that it has good immunogenicity and protection, more comprehensive protection, and more suitable for Chinese pig farms.
2. Antigen purification has no interference and solves compatibility problems: By optimizing the medium formula and fermentation parameters, it has broken through the process problems of mycoplasma high-density fermentation, and the culture level has reached a stable level of 5.0×109.0 CCU/ml. Through purification processes such as tangential flow ultrafiltration, the porcine circovirus type 2 antibody in the pig serum required for mycoplasma culture is completely removed, and the removal rate of contaminated proteins reaches 99%, which avoids interference with the immune effect of circovirus and solves the problem. Compatibility of the two antigens is difficult; PK15-B1 susceptible clonal cells are used to culture ring antigen, and the culture titer is ≥1.0×107.0TCID50/head. Through purification processes such as tangential flow ultrafiltration, the removal rate of contaminated proteins has reached more than 99%, and the antibody titer in the pig serum after immunization is equivalent to that of the imported vaccine.
3. Special water adjuvant is preferred, and dual antigens are suitable at the same time: The adjuvant of this product (FreemixTM-Gel adjuvant) uses colloidal polymer cross-linked copolymer as the material to prepare nano-microspheres with positive charge on the surface, which is adsorbed by static electricity. , It can effectively adsorb negatively charged PCV2 and mycoplasma antigens, and the adjuvant antigen complexes formed are easy to be recognized and processed by immune cells; more than 90% of the nanoparticles are within 1000 nanometers in diameter, which is ea
What's the matter? A large wave of pig farmers is suddenly very happy! It's so...2018-11-10
Recently, the editor found that many pig farmers are very happy, so I wondered, why is this?! Until, the editor learned such a blockbuster news: November 6, 2018, which took 8 years of research and development. The launch conference of the water adjuvant porcine circovirus type 2 and Mycoplasma hyopneumoniae dual inactivated vaccine was held in Luoyang.More
It is understood that this water adjuvant porcine circovirus type 2 and Mycoplasma hyopneumoniae dual inactivated vaccine was developed by Luoyang Huizhong Biotechnology Co., Ltd. relying on the National Veterinary Medicine Engineering Technology Research Center. It mainly solves the problem of pig breeding. The two major epidemic prevention problems for households allow pig farmers to invest less and make more profits when raising epidemic prevention pigs!
"Porcine circovirus type 2 and Mycoplasma hyopneumoniae dual inactivated vaccine" is Huizhong Biotechnology Co., Ltd. adhering to the business philosophy of "decent and stable operation", pursuing the development strategy of "innovating for the future" and relying on the national veterinary drug project. The Technology Research Center has achieved major scientific and technological achievements for the technology platform, has independent intellectual property rights, and has obtained the national new veterinary drug registration certificate. This result is another masterpiece achieved through continuous innovative practice since Huizhong's biological adjuvant porcine circovirus type 2 inactivated vaccine (SH strain II)!
Huizhong Biological Water Adjuvant Porcine Circovirus Type 2 Inactivated Vaccine (SH strain II), leading the domestic water adjuvant whole virus inactivated vaccine, has played a major role in the prevention and control of my country's porcine circovirus disease since the product was successfully launched , Creating good economic and social benefits; relying on the National Veterinary Medicine Engineering Technology Research Center, the company continues to carry out research and development and technological innovation and upgrades for the prevention and control of the epidemic, and develops newer and safer vaccines.
The project team used special water adjuvants and advanced seedling production technology to effectively avoid the risks of adjuvant, antigen incompatibility, stability and uniformity after single seedlings were mixed, and successfully isolated, evaluated and screened Mycoplasma strains with good immunogenicity and growth. Developed a safe and efficient water-based adjuvant suitable for two antigens, solved the three major technical problems of compatibility between PCV2 and mycoplasma antigens, and successfully developed domestic water adjuvants, porcine circovirus type 2, and mycoplasma hyopneumoniae II. Combined inactivated vaccine. The successful development and listing of this product is of great practical significance for promoting technological progress and product upgrades in the industry, and improving the level of disease prevention and control.
No wonder the pig farmers are so happy, one shot and two defenses, to increase the survival rate of pigs, so that each pig can make more money. If you are not happy, it is strange!